161 related articles for article (PubMed ID: 30050122)
1. European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation.
Engel N; Rovo A; Badoglio M; Labopin M; Basak GW; Beguin Y; Guyotat D; Ljungman P; Nagler A; Schattenberg A; Schroeder T; Schroyens W; Tischer J; Socie G; Kolb HJ; Tichelli A; Salooja N; Duarte RF;
Leukemia; 2019 Feb; 33(2):508-517. PubMed ID: 30050122
[TBL] [Abstract][Full Text] [Related]
2. Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).
Hertenstein B; Hambach L; Bacigalupo A; Schmitz N; McCann S; Slavin S; Gratwohl A; Ferrant A; Elmaagacli A; Schwertfeger R; Locasciulli A; Zander A; Bornhäuser M; Niederwieser D; Ruutu T;
Haematologica; 2005 Jul; 90(7):969-75. PubMed ID: 15996934
[TBL] [Abstract][Full Text] [Related]
3. Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature.
Wang E; Hutchinson CB; Huang Q; Lu CM; Crow J; Wang FF; Sebastian S; Rehder C; Lagoo A; Horwitz M; Rizzieri D; Yu J; Goodman B; Datto M; Buckley P
Am J Clin Pathol; 2011 Apr; 135(4):525-40. PubMed ID: 21411775
[TBL] [Abstract][Full Text] [Related]
4. Donor cell leukemia/myelodysplastic syndrome after allogeneic stem cell transplantation: a rare phenomenon with more challenges for hematologists.
Zhang S; Li L; Cao W; Li Y; Jiang Z; Yu J; Wan D
Hematology; 2021 Dec; 26(1):648-651. PubMed ID: 34474660
[TBL] [Abstract][Full Text] [Related]
5. Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Bouvier A; Ribourtout B; François S; Orvain C; Paz DL; Beucher A; Guérard A; Guardiola P; Ugo V; Blanchet O; Geneviève F; Schmidt A; Hunault-Berger M
Eur J Haematol; 2018 Oct; 101(4):570-574. PubMed ID: 30007088
[TBL] [Abstract][Full Text] [Related]
6. Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response.
Dietz AC; DeFor TE; Brunstein CG; Wagner JE
Br J Haematol; 2014 Jul; 166(2):209-12. PubMed ID: 24661075
[TBL] [Abstract][Full Text] [Related]
7. Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source.
Shiozaki H; Yoshinaga K; Kondo T; Imai Y; Shiseki M; Mori N; Teramura M; Motoji T
Bone Marrow Transplant; 2014 Jan; 49(1):102-9. PubMed ID: 24013690
[TBL] [Abstract][Full Text] [Related]
8. Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.
Hussein AA; Halkes CM; Socié G; Tichelli A; von dem Borne PA; Schaap MN; Foa R; Ganser A; Dufour C; Bacigalupo A; Locasciulli A; Aljurf M; Peters C; Robin M; van Biezen AA; Volin L; De Witte T; Marsh J; Passweg JR; Kröger N;
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1448-50. PubMed ID: 24910382
[TBL] [Abstract][Full Text] [Related]
9. [Donor cell-derived hematological malignancies after allogeneic hematopoietic stem cell transplantation].
Kato M
Rinsho Ketsueki; 2017; 58(7):813-817. PubMed ID: 28781279
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
11. Donor cell leukemia: a review.
Wiseman DH
Biol Blood Marrow Transplant; 2011 Jun; 17(6):771-89. PubMed ID: 20951819
[TBL] [Abstract][Full Text] [Related]
12. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
13. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
de Witte T; Hermans J; Vossen J; Bacigalupo A; Meloni G; Jacobsen N; Ruutu T; Ljungman P; Gratwohl A; Runde V; Niederwieser D; van Biezen A; Devergie A; Cornelissen J; Jouet JP; Arnold R; Apperley J
Br J Haematol; 2000 Sep; 110(3):620-30. PubMed ID: 10997974
[TBL] [Abstract][Full Text] [Related]
14. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
15. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Krishnan A; Bhatia S; Slovak ML; Arber DA; Niland JC; Nademanee A; Fung H; Bhatia R; Kashyap A; Molina A; O'Donnell MR; Parker PA; Sniecinski I; Snyder DS; Spielberger R; Stein A; Forman SJ
Blood; 2000 Mar; 95(5):1588-93. PubMed ID: 10688812
[TBL] [Abstract][Full Text] [Related]
16. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis.
Yabe M; Morio T; Tabuchi K; Tomizawa D; Hasegawa D; Ishida H; Yoshida N; Koike T; Takahashi Y; Koh K; Okamoto Y; Sano H; Kato K; Kanda Y; Goto H; Takita J; Miyamura T; Noguchi M; Kato K; Hashii Y; Astuta Y; Yabe H
Int J Hematol; 2021 Jan; 113(1):134-144. PubMed ID: 32949371
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
